Axsome Therapeutics, Inc. (AXSM)
AXSM Stock Price Chart
Explore Axsome Therapeutics, Inc. interactive price chart. Choose custom timeframes to analyze AXSM price movements and trends.
AXSM Company Profile
Discover essential business fundamentals and corporate details for Axsome Therapeutics, Inc. (AXSM) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
19 Nov 2015
Employees
712.00
Website
https://www.axsome.comCEO
Herriot Tabuteau
Description
Axsome Therapeutics, Inc. is a biopharmaceutical company dedicated to discovering and advancing innovative treatments for a range of central nervous system (CNS) disorders within the United States. Its robust product pipeline features several promising candidates, including: AXS-05, an investigational therapy currently being developed for major depressive disorder and treatment-resistant depression. This compound is also in Phase III clinical evaluation for Alzheimer's disease agitation and has successfully finished Phase II trials investigating its use for smoking cessation. AXS-07, a novel, orally administered, rapidly-acting investigational medicine that employs multiple mechanisms of action. It has concluded two Phase III studies for the acute treatment of migraine attacks. AXS-12, a selective and potent norepinephrine reuptake inhibitor, which is presently undergoing a Phase III trial for narcolepsy. AXS-14, an oral investigational drug, advancing through Phase III trials for the management of fibromyalgia. Axsome Therapeutics also engages in a research collaboration with Duke University to further assess AXS-05's potential in smoking cessation. The company, established in 2012, has its main offices in New York, New York.
AXSM Financial Timeline
Browse a chronological timeline of Axsome Therapeutics, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 10 Aug 2026
EPS estimate is -$0.85, while revenue estimate is $221.89m.
Earnings released on 4 May 2026
EPS came in at -$1.26 falling short of the estimated -$0.85 by -48.24%, while revenue for the quarter reached $189.40m , missing expectations by -0.79%.
Earnings released on 23 Feb 2026
EPS came in at -$0.71 falling short of the estimated -$0.70 by -1.43%, while revenue for the quarter reached $194.70m , beating expectations by +0.69%.
Earnings released on 3 Nov 2025
EPS came in at -$0.94 falling short of the estimated -$0.82 by -14.63%, while revenue for the quarter reached $170.99m , missing expectations by -10.63%.
Earnings released on 4 Aug 2025
EPS came in at -$0.92 surpassing the estimated -$1.00 by +8.00%, while revenue for the quarter reached $150.04m , beating expectations by +7.16%.
Earnings released on 5 May 2025
EPS came in at -$0.80 surpassing the estimated -$1.26 by +36.51%, while revenue for the quarter reached $121.46m , missing expectations by -13.51%.
Earnings released on 18 Feb 2025
EPS came in at -$0.96 surpassing the estimated -$1.00 by +4.00%, while revenue for the quarter reached $118.77m , missing expectations by -0.62%.
Earnings released on 12 Nov 2024
EPS came in at -$1.34 surpassing the estimated -$1.38 by +2.90%, while revenue for the quarter reached $104.76m , beating expectations by +6.50%.
Earnings released on 5 Aug 2024
EPS came in at -$1.24 surpassing the estimated -$1.30 by +4.62%, while revenue for the quarter reached $87.17m , beating expectations by +0.28%.
Earnings released on 6 May 2024
EPS came in at -$1.09 surpassing the estimated -$1.20 by +9.17%, while revenue for the quarter reached $75.00m , missing expectations by -13.46%.
Earnings released on 20 Feb 2024
EPS came in at -$0.73 surpassing the estimated -$1.21 by +39.67%, while revenue for the quarter reached $71.53m , beating expectations by +5.88%.
Earnings released on 6 Nov 2023
EPS came in at -$1.32 falling short of the estimated -$1.24 by -6.45%, while revenue for the quarter reached $57.79m , beating expectations by +3.67%.
Earnings released on 7 Aug 2023
EPS came in at -$1.00 surpassing the estimated -$1.24 by +19.35%, while revenue for the quarter reached $46.70m , beating expectations by +14.10%.
Earnings released on 8 May 2023
EPS came in at -$0.22 surpassing the estimated -$1.13 by +80.53%, while revenue for the quarter reached $94.58m , beating expectations by +255.28%.
Earnings released on 27 Feb 2023
EPS came in at -$1.28 falling short of the estimated -$1.18 by -8.47%, while revenue for the quarter reached $24.37m , beating expectations by +12.03%.
Earnings released on 7 Nov 2022
EPS came in at -$1.03 surpassing the estimated -$1.10 by +6.36%, while revenue for the quarter reached $16.85m , beating expectations by +1.26%.
Earnings released on 9 Aug 2022
EPS came in at -$1.06 surpassing the estimated -$1.19 by +10.92%, while revenue for the quarter reached $8.82m , beating expectations by +27.49%.
Earnings released on 2 May 2022
EPS came in at -$1.03 falling short of the estimated -$1.02 by -0.98%.
Earnings released on 1 Mar 2022
EPS came in at -$0.90 surpassing the estimated -$0.99 by +9.09%.
Earnings released on 8 Nov 2021
EPS came in at -$0.93 surpassing the estimated -$0.94 by +1.06%.
Earnings released on 9 Aug 2021
EPS came in at -$0.86 surpassing the estimated -$0.88 by +2.27%.
AXSM Stock Performance
Access detailed AXSM performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.
